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Abstract
 
Adoptive transfer of ovalbumin (OVA)-specific T cells from the DO.11 TCR transgenic
mouse on a Rag
 
 
 
/
 
 
 
 background into mice expressing OVA in pancreatic islet cells induces
acute insulitis and diabetes only if endogenous lymphocytes, including regulatory T cells, are
removed. When wild-type OVA-specific/Rag
 
 
 
/
 
 
 
 
 
T cells, which are all CD25
 
 
 
, are transferred
into islet antigen–expressing mice, peripheral immunization with OVA in adjuvant is needed
to induce diabetes. In contrast, naive CTLA-4
 
 
 
/
 
 
 
/Rag
 
 
 
/
 
 
 
 OVA-specific T cells (also CD25
 
 
 
)
develop into Th1 effectors and induce disease upon recognition of the self-antigen alone.
These results suggest that CTLA-4 functions to increase the activation threshold of autoreactive T
cells, because in its absence self-antigen is sufficient to trigger autoimmunity without peripheral
immunization. Further, CTLA-4 and regulatory T cells act cooperatively to maintain tolerance,
indicating that the function of CTLA-4 is independent of regulatory cells, and deficiency of
both is required to induce pathologic immune responses against the islet self-antigen.
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Introduction
 
Multiple mechanisms are known to induce tolerance in
mature T cell populations in peripheral lymphoid tissues.
These mechanisms include anergy, deletion, and suppres-
sion by regulatory T (Treg) cells (1–4). We and others
have shown previously that the inhibitory T cell receptor,
CTLA-4, plays an essential role in maintaining unrespon-
siveness to tolerogenic forms of foreign and self-antigens
(5–7). However, it is still not clearly established if CTLA-4
limits the magnitude of initial T cell activation or inhibits
continued T cell expansion and differentiation into effector
cells. Many investigators have also demonstrated a critical
role of Treg cells in maintaining tolerance to a variety of
self-antigens, including islet antigens (8, 9), but again the
mechanisms by which Treg cells inhibit responses of autore-
active lymphocytes are not well established.
Most autoimmune diseases show complex, multigenic
patterns of susceptibility. The existence of multiple suscep-
tibility genes suggests that several pathways of self-tolerance
need to be disrupted in order to trigger pathologic autore-
activity. In this study, we have examined the consequence
of deleting CTLA-4 and eliminating Treg cells on the de-
velopment of diabetes in a transgenic mouse model. Our
results show that in the absence of an exogenous immuno-
genic stimulus acute, severe diabetes develops only if both
CTLA-4 and Treg cells are nonfunctional. The cooperative
role of these two tolerogenic pathways suggests that they
serve distinct functions, perhaps at different stages of the T
cell response.
 
Materials and Methods
 
Mice.
 
DO11.10 TCR transgenic mice were purchased from
Jackson Laboratory, and Rag2
 
 
 
/
 
 
 
 mice were purchased from
Taconic Laboratories. Rat insulin promoter (RIP)-mOVA/Balb/c
mice (referred to as RIP-mOVA mice), expressing OVA under
the control of the RIP, were provided by Dr. William Heath
(The Walter and Eliza Hall Institute of Medical Research, Mel-
bourne, Australia). The CTLA-4
 
 
 
/
 
 
 
DO11.10 mouse has been
described previously (10). RIP-mOVA mice, CTLA-4
 
 
 
/
 
 
 
DO.11
mice, and the DO11.10 TCR transgenic mice were bred onto a
Rag2
 
 
 
/
 
 
 
 background. DO.11 homozygous mice were bred with
the RIP-mOVA mice to generate DO.11 
 
 
 
 RIP-mOVA mice.
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All mice were bred onto the Balb/c background for at least nine
generations. Mice were housed in the University of California,
San Francisco animal facility according to institutional guidelines.
 
Flow Cytometry. 
 
Antibodies for flow cytometry were KJ1-
26-APC, CD4-PerCP, CD4-PeCy5.5 (Caltag Laboratories),
CD62L (PE and FITC), CD25 (PE and FITC), and IFN
 
 
 
-PE. All
antibodies were purchased from BD Biosciences unless otherwise
stated. For intracellular IFN
 
 
 
 stains, cells (5 
 
 
 
 10
 
6
 
/ml) were cul-
tured in 200 
 
 
 
l complete medium (RPMI 1640 supplemented
with 1 mM glutamine, penicillin, streptomycin, nonessential
amino acids, sodium pyruvate, HEPES [all from Life technolo-
gies], 10% FCS [Sigma-Aldrich], and 5 
 
 
 
 10
 
 
 
5
 
 M 
 
 
 
-mercapto-
ethanol) and stimulated with 1 
 
 
 
g/ml OVA peptide (residues 323–
339) for a total of 6 h. Brefeldin A (10 
 
 
 
g/ml) (Epicenter) was
added for the last 3 h of incubation. The cells were then surface
stained with CD4-PerCP and the clonotypic antibody KJ1-26-
APC, fixed in 1% paraformaldehyde, permeabilized with 0.5%
saponin (Sigma-Aldrich), and stained for intracellular IFN
 
 
 
 and in-
tracellular KJ1-26, since the TCR is internalized upon activation.
 
Adoptive Transfers and Immunization. 
 
For T cell transfers,
LNs (axillary, brachial, mesenteric, popliteal, and submandibular)
and spleens were pooled, red cells lysed, and single cell suspen-
sions made. The cells were stained with CD4-PerCP and KJ1-
26-APC to determine the number of DO.11 cells. Indicated
numbers of cells were injected i.v. through the tail vein. Where
indicated, mice were immunized s.c. in the flank, 24 h after
adoptive transfer with 200 
 
 
 
g OVA peptide emulsified in IFA
(Difco). For transfers of CD25
 
 
 
 and CD25
 
 
 
 DO.11 cells, pooled
LN and spleen cells were stained with CD4-PeCy5.5, KJ1-26-
APC, CD25-PE, and CD62L-FITC. Cells were purified us-
ing high speed sorting (MoFlo; Cytomation) to separate
CD25
 
 
 
CD62L
 
hi
 
 DO.11 (Treg cells) and CD25
 
 
 
CD62L
 
hi
 
 DO.11
(responder) populations.
 
Monitoring for Diabetes.
 
Adoptively transferred mice were fol-
lowed for the development of diabetes by biweekly monitoring
of blood glucose levels using an Elite glucometer (Bayer Corp.).
 
Histology.
 
Mice were killed using CO
 
2
 
 narcosis, and the pan-
creas was removed aseptically. For hematoxylin and eosin stain-
ing, the tissues were fixed in 10% phosphate-buffered formalin.
For immunohistochemistry, acetone-fixed frozen tissues were
stained with KJ1-26-biotin (Caltag Laboratories) followed by al-
kaline phosphate-conjugated streptavidin (BD Biosciences) to de-
tect DO.11 cells. Sections were observed under light microscopy.
Severity of insulitis was measured by the extent of islet infiltration
using the criteria: no infiltration, infiltration around the periph-
ery, or invasive infiltration.
 
Statistics.
 
The statistical significance of differences between
groups was determined using the Student’s 
 
t
 
 test.
 
Results and Discussion
 
CTLA-4
 
 
 
/
 
 
 
 DO.11 T Cells Induce Diabetes without Im-
munization.
 
We have previously shown that OVA-spe-
cific DO.11/Rag
 
 
 
/
 
 
 
 cells induce acute diabetes only in
Rag
 
 
 
/
 
 
 
 RIP-mOVA recipients (not in Rag
 
 
 
/
 
 
 
 littermates)
and that peripheral (s.c.) immunization with OVA in adju-
vant is required (unpublished data). In striking contrast,
 
Figure 1.
 
Naive CTLA-4
 
 
 
/
 
 
 
 DO.11 T cells induce diabetes in a lym-
phocyte-deficient recipient, whereas naive wild-type DO.11 T cells require
a priming signal. Naive CTLA-4
 
 
 
/
 
 
 
 DO.11 (A) or wild-type DO.11 cells
(B) (10 million per mouse) were transferred into either RIP-mOVA or
RIP-mOVA/Rag
 
 
 
/
 
 
 
 recipients, and some mice were immunized s.c.
with 200 
 
 
 
g OVA peptide in IFA as indicated. The development of dia-
betes, measured by increase in blood glucose levels, is shown. The data
represent the combined results of two independent experiments with a
total of six RIP-mOVA/Rag
 
 
 
/
 
 
 
 and three RIP-mOVA recipients per
experimental group. In A, the blood glucose levels in RIP-mOVA versus
RIP-mOVA/Rag
 
 
 
/
 
 
 
 
 
recipients were significantly different (P 
 
  
 
0.0002);
in B, the blood glucose levels in the immunized RIP-mOVA/Rag
 
 
 
/
 
 
 
mice were different from unimmunized mice (P 
 
  
 
0.012) and from im-
munized RIP-mOVA mice (P 
 
  
 
0.0124). Note that the increased levels
seen after transfer of wild-type DO.11 cells and immunization were not
different from those after transfer of CTLA-4
 
 
 
/
 
 
 
 
 
DO.11 cells and no im-
munization (P 
 
  
 
0.376). (C) Wild-type and CTLA-4
 
 
 
/
 
 
 
 DO.11 T cells
are phenotypically naive; plots shown were gated on KJ1-26
 
 
 
 cells. 
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Figure 2. CTLA-4 /  DO.11
T cells cause severe insulitis in
RIP-mOVA/Rag /  mice. Na-
ive wild-type or CTLA-4 / 
DO.11 T cells (10 million per
mouse) were transferred into
RIP-mOVA/Rag /  recipients
and immunized with OVA pep-
tide and IFA where indicated.
The mice were killed 13 d after
transfer, and the pancreas were
either formalin fixed and stained
with hematoxylin and eosin
(left) or frozen, acetone fixed,
and stained with KJ1-26 (right)
and observed under 40  magni-
fication. Wild-type DO.11 T
cells (A and B); wild-type
DO.11 T cells and immunized
with OVA peptide   IFA (C
and D); CTLA4 /  DO.11 T
cells (E and F). Representative
sections for each experimental
group are shown.
Figure 3. Transferred wild-type and CTLA-4 / DO.11
T cells show similar activation profiles on encountering
antigen. Naive CTLA-4 /  DO.11 or wild-type DO.11
cells (10 million per mouse) were transferred into RIP-
mOVA/Rag /  recipients, and some mice were immu-
nized s.c. with 200  g OVA peptide in IFA as indicated.
Peripheral (PLN) and pancreatic (PANC) LNs were har-
vested 3 d later and cells were stained for CD4 and KJ1-26
and CD62L (A) and CD25 (B) expression. Plots shown are
gated on KJ1-26  cells. Numbers refer to the percentage
of positive cells in the quadrant. 
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we show here that transfer of T cells from CTLA-4
 
 
 
/
 
 
 
DO.11/Rag
 
 
 
/
 
 
 
 donors induced diabetes in RIP-mOVA/
Rag
 
 
 
/
 
 
 
 recipients in the absence of peripheral immu-
nization (Fig. 1, A compared with B). Importantly, the
CTLA-4
 
 
 
/
 
 
 
 T cells were not diabetogenic in lymphocyte-
sufficient RIP-mOVA recipients, suggesting that even
CTLA-4
 
 
 
/
 
 
 
 T cells can be controlled by Treg cells (refer-
ence 11 and Fig. 1 A).
A possible explanation for the increased pathogenicity of
the CTLA-4
 
 
 
/
 
 
 
 T cells is that these cells are activated by
endogenous antigens before adoptive transfer. However,
as shown previously (5) both wild-type and CTLA-4
 
 
 
/
 
 
 
DO.11 T cells on a Rag
 
 
 
/
 
 
 
 background express high levels
of CD62L and undetectable levels of CD25 and are thus
phenotypically and functionally naive (Fig. 1 C). It is also
conceivable that CTLA-4 is involved in the function of
Treg cells (11, 15), and therefore, deletion of CTLA-4 ab-
rogates regulatory function in the population of transferred
DO.11 cells. However, all the experiments have been done
with DO.11 cells from DO.11/Rag
 
 
 
/
 
 
 
 mice. In these
“monoclonal mice,” there are no CD25
 
 
 
 cells (Fig. 1 C
and reference 12) because there is no source of antigen that
developing cells might encounter. Thus, the effect of elim-
inating CTLA-4 cannot be on regulatory cells and must be
on effector T cell activation. Furthermore, these results
show that in the absence of CTLA-4, a transgene-encoded
self-antigen alone is sufficient to initiate T cell responses
and cause disease in an animal lacking endogenous T cells.
 
Activation of Antigen-specific T Cells.
 
Histological exami-
nation of the pancreas from adoptive transfer recipients
showed severe insulitis with massive infiltration of DO.11
cells only when CTLA-4
 
 
 
/
 
 
 
 T cells were transferred into
RIP-mOVA/Rag
 
 
 
/
 
 
 
 mice (Fig. 2, E and F) or when wild-
type DO.11 cells received a priming signal with OVA pep-
tide and IFA (Fig. 2, C and D). When the transferred cells
were wild-type DO.11 T cells, there was mild insulitis
with infiltration predominantly around the periphery of the
islets (Fig. 2, A and B).
We next examined the DO.11 cells in peripheral and
pancreatic LNs by staining and flow cytometry. At day 3
posttransfer, wild-type DO.11 cells remained phenotypi-
cally naive in both the peripheral and pancreatic LNs if the
mice were not immunized. After immunization, the wild-
type DO.11 cells down-regulated CD62L and up-regu-
lated CD25, both markers of activation (Fig. 3,
 
 
 
A and
B). Strikingly, the CTLA-4
 
 
 
/
 
 
 
 DO.11 cells showed a sim-
ilar pattern of activation, especially in the pancreatic LNs
(where cells may encounter antigen), even in the absence
of immunization (Fig. 3, A and B). At later time points,
both wild-type and CTLA-4
 
 
 
/
 
 
 
 DO.11 cells showed equal
expansion in Rag
 
 
 
/
 
 
 
 hosts (Fig. 4 A), both in the periphery
and in the pancreatic LN, the site of antigenic stimulation.
This expansion was likely due to homeostatic proliferation
seen in lymphopenic recipient animals rather than stimula-
tion by self-antigen. However, the CTLA-4
 
 
 
/
 
 
 
 T cells
showed a significantly higher frequency of IFN
 
 
 
-produc-
ing cells in the pancreatic LN than did wild-type DO.11
cells (Fig. 4 B). Thus, CTLA-4 normally controls the de-
velopment of self-antigen–reactive T cells into pathogenic
effectors. These results, together with the development of
diabetes as shown in Figs. 1, A and B, demonstrate that in
order for antigen-specific T cells to proliferate in response
to a self-antigen, differentiate into effector cells, infiltrate
the antigen-expressing tissue, and induce acute disease,
both CTLA-4 and Treg cells have to be nonfunctional.
The striking difference between naive wild-type and
CTLA-4 /  cells in the induction of disease in a lym-
phopenic host led to the question: do CTLA-4 and Treg
cells control distinct stages in antigen-specific T cell ac-
tivation, expansion and/or differentiation? To address
the influence of CTLA-4 in the presence of endogenous
Treg cells, we examined the accumulation of wild-type or
CTLA-4 /  DO.11 cells adoptively transferred into RIP-
Figure 4. T cell activation in the absence of CTLA-4 and endogenous
lymphocytes. Naive wild-type or CTLA-4 /  DO.11 T cells (10 million
per mouse) were transferred into either RIP-mOVA or RIP-mOVA/
Rag /  recipients. Mice were killed on day 13, and pancreatic and periph-
eral LN cells were stained for the presence of KJ1-26 CD4  cells or re-
stimulated with 1  g/ml OVA peptide for 6 h, and stained for intracellular
IFN . Shown are DO.11 cells as the percentage of total mononuclear cells
recovered from peripheral and pancreatic LNs of RIP-mOVA/Rag / 
mice (A) or RIP-mOVA recipients (C). IFN -producing DO.11 cells as
the percentage of total KJ CD4  cells in either pancreatic or peripheral
LNs of RIP-mOVA/Rag /  (B) or RIP-mOVA (D) recipients. The data
represent pooled results of two independent experiments using a total of six
RIP-mOVA/Rag /  and three RIP-mOVA recipients per experimental
group. In A, no difference was observed in numbers of wild-type and
CTLA-4 /  DO.11 cells recovered from the peripheral (P   0.09) or pan-
creatic LNs (P   0.08). In B, CTLA-4 /  cells recovered from the pancreatic
LN produced significantly more IFN  that wild-type cells (P   0.007).Eggena et al. Brief Definitive Report 1729
mOVA hosts. As is evident in Fig. 4 C, the presence of en-
dogenous lymphocytes prevented expansion of both wild-
type DO.11 and CTLA-4 /  DO.11 T cells, both in the
periphery and at the site of antigenic stimulation, the pan-
creatic LN. In addition, the cells did not differentiate into
effectors, indicated by the lack of IFN  production (Fig. 4
D). Thus, both Treg cells and CTLA-4 control inappropri-
ate T cell expansion and effector differentiation in response
to a self-antigen, and it does not appear that they regulate
different components of the T cell response, e.g., expan-
sion and effector cell development.
Treg Cells Prevent Disease Induced by CTLA-4 /  DO.11
T Cells. Balb/c animals are relatively resistant to autoim-
mune disease, possibly due to high activity of Treg cells
(12). As demonstrated earlier (Figs. 1, A and B), we have
never been able to break tolerance and induce diabetes in
Balb/c animals that have intact lymphoid compartments.
To confirm that acute diabetes required a deficiency of
Treg cells, we asked if purified Treg cells could protect
Rag-deficient animals from diabetes. To reconstitute Treg
cells, we isolated OVA-specific CD25  DO.11 T cells
from DO.11   RIP-mOVA mice, as described previously
(13), and cotransferred these with CTLA-4 /  DO.11 T
cells into RIP-mOVA Rag /  recipients. As shown in Fig.
5 A, the CD25  DO.11 T cells completely prevented
disease induction by the CTLA-4 /  T cells, whereas
cotransfer of CD25  DO.11 cells was not protective.
These results are consistent with the view that RIP-
mOVA/Rag /  mice develop disease because they lack
CD25  Treg cells. Although it has been shown that cells
transferred to lymphopenic animals are prone to induce au-
toimmune disease chiefly due to their homeostatic prolifer-
ation in this environment (14), we doubt that homeostatic
proliferation alone is sufficient to induce disease in our
model, since only cotransfer of CD25  but not CD25  T
cells had an inhibitory effect on the progression of diabetes.
Furthermore, the recovery of DO.11 cells was not sig-
nificantly different in the pancreatic and peripheral LNs
of mice regardless of whether they received CD25  or
CD25  DO.11 cells (Fig. 5 B).
The experiments in this work show that wild-type, anti-
gen-specific T cells attack antigen-expressing islets and
cause acute disease only if the T cells are first activated by
intentional peripheral immunization with the same antigen
in adjuvant. However, CTLA-4 /  T cells are pathogenic
even without such immunization, implying that in the ab-
sence of CTLA-4, a self-antigen behaves like an immuno-
gen. The pathogenicity of both immunized wild-type T
cells and naive CTLA-4 /  T cells is prevented by the
presence of endogenous Treg cells. Since both CTLA-4
and Treg cells must be absent in order to result in severe
disease, these results suggest that the two mechanisms of
tolerance do not serve the same role. Thus, although it has
been suggested that CTLA-4 is involved in the suppressive
function of Treg cells (11, 15), our results indicate that this
cannot be the only function of CTLA-4.
A likely model for the cooperativity of CTLA-4 and
Treg cells is that these inhibitory influences may act at dif-
ferent stages in the life of a T cell. A major function of
CTLA-4 may be to increase the threshold for initial T cell
activation (16), such that self-antigens by themselves are in-
capable of activating naive T cells. Thus, CTLA-4 would
prevent normal DO.11 cells from being pathogenic unless
its inhibitory effect was overcome by immunization with
adjuvant. This role is consistent with the finding that wild-
type T cells are not pathogenic unless they are first exposed
to peripheral immunization with antigen and adjuvant, but
CTLA-4 /  T cells are pathogenic after encounter with
self-antigen alone. Treg cells may function later in T cell
responses to block proliferation and differentiation at the
site of self-antigen, regardless of the initiating trigger. This
is why both activated wild-type T cells and naive CTLA-
4 /  T cells are prevented from causing disease if Treg cells
are present. It will be important to develop systems for ad-
dressing the possible sequential function of different toler-
ance mechanisms and to determine if genetic polymor-
phisms of CTLA-4 (17) need to be complemented by
deficiencies of Treg cells in order to induce spontaneous
autoimmune diseases in humans and experimental models.
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Figure 5.  Treg cells prevent induction of diabetes in-
duced by CTLA-4 /  DO.11 T cells. (A) Naive CTLA-4 / 
DO.11 cells (1.5 million) were transferred into RIP-
mOVA/Rag /  mice along with 0.75 million of either
CD25  or CD25  DO.11 T cells. The mice were followed
for the development of diabetes. (B) DO.11 cells, shown as a
percentage of total mononuclear cells, recovered from RIP-
mOVA/Rag /  mice 18 d posttransfer with 1.5 million
CTLA-4 /  DO.11 cells and 0.75 million of either CD25 
or CD25  DO.11 T cells. The data represent pooled results
of two independent experiments with three to four mice per
experimental group. In A, blood glucose levels seen after
transfer of CTLA-4 /  cells were significantly different from
CTLA-4 /     CD25  cells (P    0.05) but not from
CTLA-4 /    CD25  cells (P   0.252).CTLA-4 and Treg Cells in Tolerance 1730
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